Plasma Cell Myeloma: Biochemical Insights into Diagnosis, Treatment, and Smart Nanocarrier-Based Therapeutic Development.

Pharmaceutics · 2025 · PMC12737029 · PMID 41471085

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These modifications are highly significant, as they reflect the molecular heterogeneity of the tumor and may contribute to the variability in patient responses to targeted therapies [ 68 , 69 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.